Picture of Vitrolife AB logo

VITR — Vitrolife AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Sweden's Vitrolife Q4 revenue falls 7% due to currency impact

Overview

Sweden medical devices firm's Q4 revenue fell 7% in SEK due to currency impact

Net income for Q4 impacted by impairment charge, resulting in a loss

EBITDA margin for Q4 decreased to 22% from 35.1%

Outlook

Vitrolife did not provide specific guidance for future quarters or years

Result Drivers

CURRENCY IMPACT - Significant negative currency effect led to a 7% decrease in Q4 sales in SEK, despite 6% organic growth in local currencies

REGIONAL GROWTH - Sales in local currencies grew 9% in Americas and 10% in APAC, while EMEA saw a 1% decline excluding discontinued business

PRODUCT GROUP PERFORMANCE - Consumables and Technologies product groups saw growth of 10% and 6% respectively in local currencies, while Genetics grew 1%

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 RevenueSEK 891 mln
Q4 EPS-SEK 39.24
Q4 Net Income-SEK 5.31 bln
Q4 EBITDASEK 196 mln
Q4 EBITDA Margin22.00%
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy" Wall Street's median 12-month price target for Vitrolife AB is SEK160.00, about 36.6% above its February 2 closing price of SEK117.10 The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 41 three months ago Press Release: ID:nWkr8fWFCw For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Vitrolife AB

See all news